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Summary 
Strategies are being sought that allow the induction of specific tolerance to allogeneic trans- 
plants without affecting other immune functions. The so-called veto effect has been described 
as one such technology where CD8 + cells suppress responses of  class I MHC-restricted T-lympho- 
cyte precursors to antigens expressed by those CD8 + veto cells. Yet, veto inhibition will not be 
able to provide complete tolerance to allogeneic grafts since it only operates on cell populations 
that express CD8. Other types of cells prevalent in most organs express different tissue-specific 
antigens that are recognized by alloreactive T-cells. Therefore, complete tolerance to an alloge- 
neic transplant can only be achieved if all cellular components within the graft acquire the im- 
mune-inhibitory function. Here, we studied whether the veto effect could be exploited for this 
purpose nevertheless. We produced a hybrid antibody (HAb) combining a mAb specific for a 
class I MHC molecule with a soluble CD8 molecule. We found that this HAb specifically and 
effectively transferred veto inhibition to different stimulator cell populations.  Thus, we have 
developed a strategy that promises to selectively and completely tolerize graft-specific CTLs 
without affecting normal immune responses. 
I 
n  a clinical situation, survival of allogeneic grafts is best 
achieved by the administration  ofimmunosuppressive drugs, 
e.g., cyclosporine A, corticosteroids, etc. This regimen also 
impairs the patient's defenses against  infectious challenges. 
Strategies are, therefore, being sought that successfully in- 
duce specific nonresponsiveness (tolerance) to the transplant. 
The veto effect has been described as one such mechanism 
in which CD8 + cells suppress  responses of class I MHC- 
restricted  T-lymphocyte precursors  to  antigens  expressed 
by those CD8 + veto cells (Fig.  1 A) (1-3). The suppression 
is both antigen-specific (2, 3) and MHC-restricted (4), and 
results  from the unidirectional recognition of the veto cell 
by the  responding cytotoxic T-lymphocyte, but not vice 
versa (3, 4).  It can be exerted by CD8 § cells isolated from 
either bone marrow  (BM) 1 or the  spleen  (2,  3,  5).  This 
suppression functions in  vitro  and  in vivo  (6,  7),  is  very 
powerful in selectively removing T  cells from the periph- 
eral repertoire (8-12), yet does not affect negative selection 
in the thymus (13).  Injection of veto cells has been shown 
to prolong graft survival in several animal models  (10-12, 
14).  Class I MHC-restricted T  cells with a wide spectrum 
*Abbreviations used in this paper: BM, bone marrow; HAb, hybrid  antibody; 
SPDP, N-succinirnidyl-3-  (1-pyridyldithio)-propionate. 
of specificities to allo-antigens, minor and haptenated his- 
tocompatibility antigens have been inhibited by veto cells 
(6). Activated CD8 + T  cells represent the most active in- 
hibitor population (6, 7). Veto activity is linked to the pres- 
ence of the  CD8  c~-chains  such  that the veto function is 
lost if expression of CD8 is deleted, yet is reconstituted by 
reexpression  of the  CD8  &-chain  (15).  The  function  of 
CD8 + veto cells is independent of their own recognition 
specificity (6, 7). 
Activation of CD8 + class I MHC-restricted T  cells de- 
pends on coengagement of the TCR with the CD8 acces- 
sory  molecule  (16,  17).  Disturbance  of this  interaction 
complex prevents T cell activation.  Indeed, anti-CD8 mAb as 
well as antibodies (and peptides) blocking the CD8-binding 
site on class I MHC molecules inhibit the induction of T 
cells (18-20). Therefore, one could hypothesize that CD8 on 
stimulator cells, as in the veto effect, saturates  CD8-binding 
sites on class I MHC molecules expressed by these cells. CTL 
precursors would be prevented from coengaging TCR. and 
CD8  on the stimulators' class I  MHC molecules. Yet, an 
alternative hypothesis has been offered. Experiments have 
been performed that suggest  that  T  cells  are  deleted that 
have received a signal  through their T  cell receptor com- 
plex and at the same time through the o~3 domain of their 
class I MHC molecules (21).  Such a trigger is delivered by 
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Volume 183 May 1996 1973-1980 Figure 1.  Schematic  representation  of HAb-mediated  veto.  (A)  On 
conventional  veto-cells the CD8 accessory molecule is endogenously ex- 
pressed. (B) A HAb, here exemplified by 15-CD8,  delivers CD8 to a cell 
surface via its binding  to a class I MHC molecule. 
CD8 on stimulator cells or by antibodies to this domain (21). 
Nevertheless,  both  theories  predict  that  CD8  molecules 
delivered to any stimulator cell will veto reactive T  cells. 
Therefore, we produced a hybrid antibody (HAb) whose 
antibody moiety targets expression of the CD8  coreceptor 
onto  cells  (Fig.  1  B).  Here,  we  demonstrate  its  ability to 
transform  stimulator  cells  into  inhibitory cells  resulting in 
the specific suppression of class  I  MHC-restricted  T  cells. 
Thus,  we  have  developed  a  strategy  to  specifically induce 
tolerance of class I MHC-restricted T  cells. 
Materials and Methods 
Animals.  Female  mice  (DBA/1,  BALB/c,  C57BL/6)  8  to 
10 wk of age were purchased from the Jackson Laboratory (Bar 
Harbor,  ME).  T  cell receptor  transgenic  (TCp`tr~,s+)  mice  ex- 
pressing the  2C-TCp`tran~  had  been obtained from  Dr.  D.  Loh 
(Washington University, St. Louis, MO), and were bred onto the 
permissive H-2  b background (22). 
Hybrid Antibody Constructs.  Dimers  of  the  soluble  human 
CD8  o~-chain  were  harvested  from  CHO-DL  cells  transfected 
with  the  human  CD8  cx-chain truncated at  position  146  (23). 
The cell line was maintained in serum-free, protein-free S2770- 
medium (Sigma Chem.  Co., St. Louis, MO).  Soluble CD8 was 
purified by a modification of the pubhshed method. Two  (2) li- 
ters of tissue culture supernatant were filtered, adjusted to pH 8.5 
and adsorbed to a Mono-Q-Sepharose column (Pharmacia,  Uppsala, 
Sweden). The column flow-through was loaded onto a Wheat- 
germ-Lectin-Sepharose column (Pharmacia), and CD8 was eluted 
using 5% N-acetyl-glucosamine. The eluate was dialyzed against 
20  mM NaC2H30 2 (pH  5.4;  Sigma),  concentrated, and loaded 
onto Mono-S-Sepharose (Pharmacia) preequilibrated with 20 mM 
Hepes (pH 8.0; Sigma). Soluble CD8 was eluted as the first peak 
ofa NaCl-gradient (20 mM to 500 raM; Sigma) in 20 mM Hepes 
(pH 8.0) and dialyzed against PBS. The purity of the CD8 or-chain 
preparation,  as  analyzed on SDS-PAGE,  was  higher  than 99%. 
The mAb 15-5-5 is reactive with H-2D  a, yet not with H-2 mol- 
ecules of the H-2  b and H-2q haplotype (24).  It was purified from 
tissue  culture  supernatant  on  a  protein  A-Sepharose  column 
(Pharmacia) using standard protocols (25).  Soluble CD8 and the 
mAb 15-5-5 were cross-linked as described previously with  the 
help  of the  heterobifunctional cross-linker,  N-succinimidyl-3- 
(1-pyridyldithio)-propionate (SPDP; Pharmacia) (25). Both 15-5-5 
and CD8  were  reacted  with  SPDP  at  pH  7.4.  SPDP-modified 
proteins were separated from unreacted SPDP by Sephadex G25 
column (Pharmacia) chromatography. Approximately one SPDP 
group was introduced per protein molecule. 2-pyridyl-disulphide 
groups of the mAb were reduced (at pH 5.0) to expose a reactive 
SH-group.  Then,  15-5-5 was purified on a  Sepharose  G25 col- 
umn and reacted with the modified CD8 at neutral pH. The hy- 
brid antibody constructs, for short called hybrid antibodies (HAb) 
were  analyzed on  SDS-PAGE.  Unless otherwise  indicated  the 
HAb  and  its  components were  used  at  final  concentrations of 
1 I~g/ml. 
Mixed Lymphocyte Culture and Cytotoxicity Assay.  Spleen  cells 
were harvested and single cell suspensions were prepared. Eryth- 
rocytes were lysed with Tris-buffered ammonium chloride (Sigma). 
Stimulator cells  were  irradiated (1,500  rad),  then cultured (4  ￿ 
106 cells) with responder cells (2 X  106 cells) in one well of a flat- 
bottomed  24-well plate  (Becton-Dickinson, Lincoln Park,  NJ). 
Iscove's modified Dulbecco's medium (IMDM; Sigma) was used 
as  growth  medium  supplemented  with  5  mM  Hepes,  2 mM 
glutamine, 1 mM hydroxypyruvate, 50  ~M 2-mercaptoethanol, 
non-essential amino acids,  100 IU/ml penicillin, 100 b~g/ml strep- 
tomycin, 50 p,g/ml gentamycin (Sigma), and 10% fetal bovine se- 
rum (Intergen, Purchase, NY). The cultures were incubated for 
4 d at 37~  and 7% CO  2 in a tissue-culture incubator (Forma Sci- 
entific, Marietta, Ohio). At termination of culture blast cells were 
counted. As indicated in the text, certain cultures received soluble 
CD8,  15-5-5 mAb or HAbs. To other cultures 2  ￿  10  s irradiated 
(5,000 rad)  P815 cells (BALB/c-derived mastocytoma cells) were 
added. These tumor cells had been precultured with soluble CD8 
and  15-5-5  or HAbs  at  1  ~g/ml  and had been washed  before 
their introduction to MLCs. To test for cell-mediated lympholysis, 
effector cells were incubated with 1 ￿  104 [SlCr]NaCr20a-labeled 
target cells, P815 or EL4 (C57BL/6-derived lymphoma cells) sus- 
pended in cell culture medium for 4 h in round-bottomed micro- 
titer  plates  (total  volume  0.2  ml;  Becton-Dickinson).  Varied 
numbers ofeffector cells were used resulting in different effector- 
target-ratios as indicated in the text. The plates were spun and the 
amount of SlCr-released into the supernatant was determined on 
an Automatic  Gamma  Counter  (Micromedic,  Hoorsham,  PA). 
Wells containing target cells,  but no effector cells were  used to 
determine non-specific release, and wells containing target cells in 
the  presence of 1%  Triton X-100  (Sigma)  to  measure total  re- 
lease.  Percent specific release was calculated as: [(cpm released in 
the presence of effector cells  -  cpm of non-specific release)/(cpm 
of total release  -  cpm of non-specific release)]  ￿  100. 
How Cytometry.  T-cells  were  stained  in  single  cell  suspen- 
sions as described previously (26).  They were incubated with bi- 
otinylated H57-597  (Pharmingen, San Diego, CA), which reacts 
with all oq3-TCp`s, or with biotinylated 1B2,  which specifically 
reacts with the TCP,  qaio~e, i.e., with the 2C-TCP`t  ...... followed 
by  CyChrome-coupled  streptavidin  (Pharmingen).  They  were 
counter-stained  on  ice  with  phycoerythrin-coupled  anti-CD4 
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body binding  to  cells was  analyzed  on  a  FACScan  |  (Becton- 
Dickinson, San Jose, CA) flow cytometer. As indicated in the fig- 
ures, data are given as log10 fluorescence. 
Results  and Discussion 
Previously we had demonstrated  that HAb both as het- 
eroconjugates  and  as  bi-specific  monoclonal  antibodies, 
were  able  to  modify  T  cell  responses  (25,  27).  We  had 
shown that HAbs redirected  lysis  of cytotoxic T-lympho- 
cytes  (25,  27,  28)  and induced T  cell development in the 
thymus (29).  Having established  the versatility of the HAb 
approach, we decided to adapt this technology to transfer T 
cell veto. As the veto function resides within the CD8 ac- 
cessory molecule,  i.e.,  the  CD8  a-chain,  we  coupled the 
CD8 a-chain to a mAb (15). Since the human CD8 func- 
tions within the mouse environment (30), we took advan- 
tage  of a  source  of the  human  soluble  CD8  or-chain that 
had  been  established  by  others  to  determine  its  crystal 
structure  (23). As targeting entity, we selected a mAb with 
specificity to a  mouse class  I  MHC  molecule.  This  choice 
should  enable  the  HAb  to  bind  to  virtually  all  ceils.  We 
chose the mAb 15-5-5 that reacts with class I MHC  mole- 
cules  of the  H-2  d (H-2Da),  but  not of the  H-2  b or H-2q 
haplotypes  (24).  To establish  the feasibility  of HAb-medi- 
ated  veto,  we  decided  to  produce  a  bi-specific  construct 
chemically  cross-linking  the  two  reagents  (25).  For  this 
purpose the soluble  CD8 a-chain homodimer was conju- 
gated to the purified mAb resulting in  a hybrid construct, 
here  called HAb  15-CD8.  In the  first set  of experiments, 
we tested whether  15-CD8  specifically guided the surface 
expression  of CD8  a-chains.  We  coated P815  (H-2  a)  and 
EL4 (H-2  b) cells with either  15-CD8 or with its non-con- 
jugated  components,  the  mAb  15-5-5  and  the  CD8 
c~-chain.  The  extent  of CD8-surface  expression was mea- 
sured by staining with a fluoresceinated anti-CD8 mAb. As 
depicted in Fig. 2, neither  15-CD8 nor its components led 
to an appreciable surface expression of CD8 on EL4 (H-2  b) 
cells.  Yet,  15-CD8 transferred large numbers of CD8 mol- 
ecules  onto P815  (H-2  a)  cells.  The  non-conjugated  com- 
ponents failed to do so. Thus,  15-CD8 had reacted accord- 
ing to the specificity of its antibody component,  15-5-5. It 
targeted expression of CD8 (x-chains onto cells of the H-2  a, 
yet not the H-2  b haplotype. 
Having  established  the  binding  specificity  of 15-CD8, 
we examined whether T  cell responses could also be inhib- 
ited.  Mixed lymphocyte cultures  (MLCs)  were  established 
with  BALB/c  (H-2  d)  spleen  cells  as  stimulators  and 
C57BL/6  (H-2b)  spleen  cells  as  responders.  In this  strain 
combination,  15-CD8  selectively  coats  stimulator  cells. 
The HAb and its non-linked components, CD8 and 15-5-5, 
were added at escalating concentrations into these MLCs. Af- 
ter 4  d  of incubation,  T-cells were harvested to determine 
their lyric activities towards their specific target, P815 (H-2a). 
As depicted in Fig. 3, the HAb almost completely inhibited 
the induction of  CTLs at concentrations as low as 125 ng/ml, 
whereas no significant effect was seen upon addition of the 
Figure 2.  Specificity  of 15-CD8 binding. P815 (H-2  a) (A and B) and 
EL4 (H-2  b) (C and D) cells were incubated either with the HAb 15-CD8 
(B and D) or its non-linked components, the mAb 15-5-5 and the soluble 
CD8 r  (A and C). Surface expression of  CD8 was determined with 
the help of  a directly fluoresceinated anti-CD8 mAb. 
non-linked components,  CD8 and 15-5-5. Based on these 
results  antibody  concentrations  were  adjusted  to  1  Ixg/ml 
in all other experiments.  Next, we analyzed the functional- 
ity of the  HAb in more detail.  MLCs were  supplemented 
with the HAb, soluble CD8,  15-5-5 or their combination. 
As  shown  in  Fig.  4,  addition  of soluble  CD8  and  15-5-5 
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Figure  3.  Concentration dependence of HAb-mediated inhibition of 
MLCs. Increasing  concentrations of 15-CD8 (0) or its non-linked com- 
ponents (A) were added to C56BL/6 (H-2  b) anti-BALB/c (H-2  a) MLCs. 
After 4 d cultures were harvested, and their lytic activities towards P815 
(H-2  a) cells were tested. 
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Figure 4.  Ability  of 15-CD8 to inhibit CTL induction. C57BL/6 (H-2  b) 
spleen cells were stimulated with irradiated BALB/c (H-2  a) spleen cells. 
These cultures were supplemented with the mAb 15-5-5 (V), the soluble 
CD8 ~x-chain (~7), a mixture of the non-conjugated components (A), or 
the HAb 15-CD8 (0). Controls were established in the absence of  any of 
these reagents (O). After 4 d cultures were harvested, and their lytic activ- 
ities towards P815 (H-2  d) cells were tested. 
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Figure 5.  Ability  of a hybrid construct to inhibit CTL activity induced 
by BM cells. A HAb was established using 15-5-5 F(ab')2  fragments as tar- 
geting molecule. It was added to C57BL16 (H-2  b) spleen cells that were 
challenged with irradiated BALB/c (H-2  a) BM cells (&). Control cultures 
were set up in the presence of  the non-conjugated components (C)). 
alone or in combination did not impair the development of 
C57BL/6 T-cells into specific cytotoxic effector cells.  Yet, 
15-CD8  efficiently inhibited  their stimulation  to such ex- 
tent  that  lytic  activity  towards  the  specific  target,  P815, 
could no longer be detected.  From these  results,  we drew 
the following conclusions: (a) 15-CD8 suppressed CTL-acti- 
vation  in  conventional  MLCs.  (b)  The  HAb  components 
(the mAb,  15-5-5, and the CD8 a-chain) had to be linked 
to exert  this inhibitory  effect.  The targeting MAb  15-5-5 
specifically reacts  with  the  H-2D a  class  I  MHC  molecule 
expressed  on  H-2  d stimulator  cells.  Even  if 15-5-5  were 
able to completely hide H-2D  a on BALB/c stimulator cells, 
it should not suppress responses directed towards other class 
I MHC molecules, i.e.,  H-2K  a and H-2L a.  Indeed, we did 
not observe that its  addition  significantly inhibited  the in- 
duction of anti-H-2 a allo-reactive CTLs. It is also of inter- 
est that in this (Fig.  4)  and several other experiments addi- 
tion  of the non-linked soluble CD8 alone or in addition to 
15-5-5  resuked  in  a  small  increase  in  lytic  activity.  This 
finding  might  indicate  that  soluble  CD8  competes  with 
CD8 + cells found within the splenic stimulators,  thus,  de- 
leting their veto function. 
As  HAb-mediated  inhibition  might  become  useful  in 
preventing rejection of BM grafts, we established a second 
MLC  system in  which BM  cells  acted  as  stimulator  cells. 
CD8 + cells normally found within normal BM populations 
were deleted from the BALB/c (H-2  a) BM population by 
antibody (anti-CD8) and complement treatment (31).  Then, 
the  remaining BM  cells  were used  to challenge  C57BL/6 
(H-26) spleen cells.  As depicted in Fig. 5, a HAb construct 
suppressed  the  induction  of  C57BL/6-derived  CTLs. 
These  findings  again  demonstrated  the  efficacy  of HAb- 
mediated  inhibition.  Here,  the  inhibitory  function  had 
been transferred to BM rather than spleen cells.  For this ex- 
periment,  we  had  incorporated  15-5-5  F(ab')2  fragments 
into the hybrid construct (27). Therefore, these studies also 
indicated  that  deletion  of the  Fc  portion  of the  targeting 
mAb did not interfere  with the inhibitory function. Thus, 
Fc receptor mediated  binding of 15-CD8 was not crucial 
for the observed veto. Though these experiments provided 
some  support  for  our  notion  that  HAbs  could  transform 
non-lymphoid cell into veto cells,  we addressed the validity 
of this postulate  more directly in another experiment.  For 
this  purpose,  irradiated  P815  (H-2  a)  mastocytoma  cells 
were preincubated with the HAb or its non-linked compo- 
nents, and after washing they were added to C57BL/6 (H-26) 
anti-BALB/c  (H-2 a) MLCs.  When we measured the lytic 
activity of these cultures,  we found that HAb-coated P815 
cells  had  efficiently  suppressed  CTL  responses  (Fig.  6). 
However, P815  cells  exposed to soluble  CD8 and  15-5-5 
failed to do so. As non-coated P815  did not decrease  the 
observed CTL activity, we could exclude that the observed 
inhibition  was due  to  competitive  inhibition  of the  cyto- 
toxicity assay  by p815  itself.  Therefore,  these  experiments 
demonstrated that HAbs could, indeed,  convert non-lym- 
phoid cells into veto cells. 
We  had  already  determined  that  15-CD8  specifically 
bound to cells  of the H-2  d haplotype,  and that it was able 
to  inhibit  an  allo-response.  Yet,  we  had  not  determined 
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Figure 6.  Transferring  veto-function to non-lymphoid cells. Irradiated 
P815 (H-2  a) mastocytoma cells were preincubated with 15-CD8 (O), its 
nonqinked  components, CD8 and 15-5-5, (&)  or medium ((3). After 
washing the  treated P815 cells were added to C57BL/6  (H-2  b)  anti- 
BALB/c (H-2  a) MLCs. After 4 d of culture their lyric actvities towards 
P815 cells were tested. 
whether the inhibitory function exhibited similar specific- 
ity. As the targeting component of the HAb, m_Ab 15-5-5, 
does not bind to class I MHC molecules of the H-2q haplo- 
type (24), MLCs were established in which DBA/1  (H-2q) 
cells were challenged by either BALB/c (H-2  a) or C57BL/6 
(H-2  b)  spleen  cells.  Whereas  15-CD8  bound to BALB/c 
H-2 stimulator cells,  it could not link to MHC  molecules 
on DBA/1  (H-2q). When we added the HAb to these cul- 
tures,  we  observed  that  15-CD8  selectively  inhibited  in- 
duction  of DBA/1 (H-2q)  CTLs  challenged with BALB/c 
(H-2d)  spleen  cells  (Fig.  7  A).  15-CD8  did  not  suppress 
CTL activation when added to MLCs in which C57BL/6 
(H-2  b) spleens cell had been used as stimulators  (Fig. 7/3). 
Non-conjugated  components  of  15-CD8  did  not  affect 
lyric activities of either MLC. We had, therefore,  demon- 
strated that 15-CD8 had to attach to cells to inhibit. 
Yet, these experiments had not established that the HAb 
had to react with stimulator cells.  To prove this point, two 
additional MLCs were set up, C57BL/6 anti-BALB/c (I--I-2  b 
anti-H-2  a)  and BALB/c  anti-C57BL/6  (H-2  d anti-H-2b). 
In the  first  strain  combination  15-CD8  coated  stimulator 
cells, whereas in the second one it selectively linked to re- 
sponder cells.  As seen in Fig. 8,  15-CD8 selectively inhib- 
ited MLCs when binding to stimulator cells.  However, in 
MLCs in which it was attached to responder cells vigorous 
CTL responses were induced. These experiments provided 
evidence  that  15-CD8  had  to  bind  to  stimulator  cells. 
Thus,  the binding specificity of the  hybrid construct pre- 
dicted the  direction  of its  inhibitory function.  The unidi- 
rectional  nature  of these  results  also  supported  our earlier 
contention that Fc receptor-mediated binding, if it occurred, 
was not crucial for the inhibitory function exhibited by the 
HAb. Fc receptors are expressed by cells found within both 
BALB/c  and  C57BL/6  spleens,  yet  the  HAb  selectively 
suppressed CTL precursors specific for BALB/c cells. 
The experimental system employed by us differed in one 
additional aspect from that of previous studies: other studies 
had used non-irradiated  cells as inhibitory agent because it 
had been noted that the veto-function of CD8 §  cells was 
radiosensitive  (2,  3).  In our system,  by contrast,  15-CD8 
was  perfectly  capable  of inhibiting  CTL  responses  when 
binding  to  irradiated  stimulator  cells  (Fig.  9).  Indeed,  the 
extent of suppression was comparable to that observed us- 
ing non-irradiated  cells.  If we assume  that HAb-mediated 
inhibition  and  conventional  veto  function  by  the  same 
mechanism, this difference in results can be best explained 
as  follows.  Most  investigators  studying  conventional veto 
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Figure  7.  Dependence of HAb activity on its 
ability to bind to cell surfaces. Two different MLCs 
were set up: DBA/1 (H-2q) anti-BALB/c (H-2  a) 
(.4) and DBA/I  anti-C57BL/6  (H-2  b)  (/3). They 
were supplemented with  the  HAb  (Q), its non- 
conjugated components (&)  or nothing  (C)) and 
tested for their lyric ability on P815 (H-2  a) (A) or 
EL4 (H-2  b) (B) cells. 
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Figure  8.  Specificity of  HAb-mediated  veto. 
MLCs  were  established in  two  directions: C56/ 
BL6 (H-2  b) anti-BALB/c (H-2  a) (,4) and BALB/c 
anti-C57BL/6  (B). They were supplemented with 
HAb (Q), its non-conjugated components (&) or 
nothing  (C)) and  tested for their  lytic ability on 
P815 (H-2  a) (A) or EL4 (H-2  b) (/3). 
exploited the inhibitory function ofCD8 + CTLs which are 
known  to  be  radio-sensitive.  Irradiated  T-lymphocytes 
used as veto cells in vitro are deleted early. They are, there- 
fore,  not  able to  inhibit allo-reactive T  cells that  had  re- 
mained  dormant  and are stimulated at a  later time.  HAbs 
have the ability to transfer CD8  to all stimulator cells, in- 
cluding  those  that  are  rather  radio-resistant,  e.g.,  macro- 
phages and fibroblasts. Thus,  CDS-bearing cells are present 
throughout  the entire culture period,  and have  the ability 
to veto, both T  cells stimulated early as well as those acti- 
vated late. Our conclusion that HAb-mediated veto can be 
o.1  i  ;o  loo 
E/T 
Figure  9.  Radio-resistence of HAb-mediated veto. C57BL/6  (H-2  b) 
cells were incubated with  non-irradiated (C)) or irradiated (A) BALB/c 
(H-2  a) spleen ceils. Cultures were supplemented with 15-CD8 (O, &) or 
with the non-conjugated components (￿9  A) and tested for lysis ofP815 
(H-2  d) cells. 
mediated by, for instance, macrophages and dendritic cells, 
also implies that CTL lytic functions are not crucial for T 
cell mediated veto. 
To study the fate oft  cells in HAb-mediated MLCs, we 
took advantage ofa TCR. transgenic mouse model in which 
the  vast  majority  of T  cells  expressed  the  2C-TCRt~ns 
which  recognizes  the  allo-class I  MHC  molecule  H-2L  a 
(22).  In these mice TCP~ans+  T  cells can be identified by 
the  anti-clonotypic  mAb.lB2.  Responder  TCP~ran~+  T 
cells were stimulated with irradiated BALB/c spleen cells in 
the  presence  of 15-CD8  and  its non-conjugated  compo- 
nents.  Numbers  of TCI~a,s+CD8 +  T  cells were  enumer- 
ated at the start as well as at the termination of cultures (Ta- 
ble 1).  We failed to detect an increase in the cellularity of 
cultures supplied with the hybrid constructs. Thus,  15-CD8- 
mediated similar to  conventional  veto  had  prevented  the 
expansion of reactive T  cells (13, 21). 
Based  on  these  observations,  we  believe  that  conven- 
tional veto and HAb-mediated inhibition function through 
the same mechanism. Yet, HAb-induced unresponsiveness 
might  bear some  advantages  over  conventional  veto.  Al- 
though  the conventional veto effect is extremely efficient, 
it only operates on CD8 + cells, i.e., on defined populations 
Table 1.  Inhibition  of TCRerans+  CD8  + T cells by HAb 
engagement 
Number ofTCRtr~ns+CD8 + T  cells 
Compound added  Experiment 1  Experiment 2 
15-5-5 and CD8  6.1  5< 104  6.0 X  104 
15-CD8HAb  1.2  ￿  104  1.8  ￿  104 
2  ￿  104  TCP,.~s+CD8 + T  cells were  added to  1  X  106  irradiated 
BALB/c  (H-2  d) spleen cells in the presence of the  compounds  indi- 
cated. After 4 d cultures were harvested, cells were counted and stained 
for expression of CD4, CDS, and TCP~=~ns in three-color immunofluo- 
rescence. From these informations  the numbers  of TCRtr~,,s+CD8 T 
cells were calculated. 
1978  Hybrid Antibody Mediated Veto of Cytotoxic T Lymphocyte Responses of inhibitor  cells  (2).  It has to be taken  into consideration 
that  different  types  of cells  express  unique  tissue-specific 
antigens  (32)  and that some allo-reactive T  cells recognize 
these differences (33-35). Thus, allo-responses discriminate 
between  different  tissues.  Therefore,  allo-reactive  T  cells 
exhibiting tissue-specific recognition cannot be silenced by 
the  infusion  of, for instance,  CD8 +  T  cells  as they fail to 
present antigens typical for other cell types. Complete tol- 
erance to an organ transplant is,  therefore,  not induced by 
cells  of a single type, but is best achieved if all  cells within 
the graft are transformed into inhibitory cells. As we have 
demonstrated that non-lymphoid cells can acquire the veto 
function,  HAbs will provide the necessary tool to achieve 
this  goal.  Thus,  we  have  developed  a  technology  that 
promises  to provide  specific and  complete  transplantation 
tolerance without affecting other immune functions. 
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